Pharmacological treatment options for cryopyrin-associated periodic syndromes (Q38674213)

5 September 2017

1 reference

title

Pharmacological treatment options for cryopyrin-associated periodic syndromes (English)

1 reference

5 September 2017

author name string

Emmanuelle C Landmann

series ordinal

1

1 reference

5 September 2017

Ulrich A Walker

series ordinal

2

1 reference

5 September 2017

language of work or name

English

0 references

publication date

6 June 2017

1 reference

Expert Review of Clinical Pharmacology

5 September 2017

published in

1 reference

5 September 2017

volume

10

1 reference

5 September 2017

issue

8

1 reference

5 September 2017

page(s)

855-864

1 reference

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Immunological and inflammatory functions of the interleukin-1 family

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

The inflammasomes: guardians of the body

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Inflammasomes and their roles in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Somatic NLRP3 mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Brief Report: Cryopyrin-Associated Periodic Syndrome Caused by a Myeloid-Restricted Somatic NLRP3 Mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Monocytes from familial cold autoinflammatory syndrome patients are activated by mild hypothermia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Impaired cytokine responses in patients with cryopyrin-associated periodic syndrome (CAPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1beta secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Cryopyrinopathies: update on pathogenesis and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Musculoskeletal symptoms in patients with cryopyrin-associated periodic syndromes: a large database study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Natural history and outcome in systemic AA amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Recommendations for the management of autoinflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Efficacy of anakinra in gouty arthritis: a retrospective study of 40 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Anakinra: an emerging option for refractory idiopathic recurrent pericarditis: a systematic review of published evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Canakinumab for the treatment of chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Failure of tocilizumab treatment in a CINCA patient: clinical and pathogenic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Pharmacokinetics of anakinra in subjects with different levels of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Effect of anakinra on arthropathy in CINCA/NOMID syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

IL-1β is an innate immune sensor of microbial proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Soluble receptors and cytokine antagonists in human milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

International experience of pregnancy outcomes in auto-inflammatory syndromes treated with Interleukin-1 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Cytokine traps: multi-component, high-affinity blockers of cytokine action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Use of canakinumab in the cryopyrin-associated periodic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Brief Report: Severe Inflammation Following Vaccination Against Streptococcus pneumoniae in Patients With Cryopyrin-Associated Periodic Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

A Study to Investigate the Efficacy and Safety of an Anti-Interleukin-18 Monoclonal Antibody in the Treatment of Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

The PYRIN Domain-only Protein POP1 Inhibits Inflammasome Assembly and Ameliorates Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

Anakinra treatment in drug-resistant Behcet’s disease: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2017.1338946

10.1080/17512433.2017.1338946

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference